
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss the trajectory and role of of CAR T-cell therapy within the treatment spectrum for LBCL.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, share considerations for sequencing CAR T-cell therapies in patients with LBCL, depending on treatments they have already received.
Miguel-Angel Perales, MD, shares insight into the factors he considers when deciding if a patient should receive CAR T-cell therapy in the second line.
Miguel-Angel Perales, MD, shares background on the unique design of a real-world analysis of liso-cel in LBCL in which he and his co-investigators prospectively collected retrospective data.
Caron A. Jacobson, MD, discusses the significance of a real-world follow-up analysis of liso-cel in which safety and efficacy findings in patients with comorbidities and others who were not eligible for clinical trials were consistent with those studies.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, review the impact of real-world analysis and how they may shape guidelines and clinical approaches with respect to the use of CAR T-cell therapy in LBCL.In particular, they note how continued research bolsters the safety profile of these agents.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Miguel-Angel Perales, MD, and Caron A. Jacobson, MD, share insights regarding the context and implications of the recent actions by the FDA to add boxed warnings to CAR T-cell therapies.